Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6/28/22 19:48 | 6/24/22 | OCX | Health | Diagn | In Vitro & In Vivo Diagnostic | Pura Vida Investments, LLC | NY | T | S | -103 | 1.03 | 0 | -99 | -1 | 15,907 | I | |||||||||||||||
5/19/22 17:58 | 5/18/22 | OCX | Health | Diagn | In Vitro & In Vivo Diagnostic | Yu Li | CA | O | VP Cntrl | S.d | -9 | 1.14 | 0 | -8 | -33 | 17 | D | ||||||||||||||
12/28/20 21:46 | 12/23/20 | OCX | Health | Diagn | In Vitro & In Vivo Diagnostic | Kingsley Alfred D | NY | D | S.d | -2 | 2.55 | 0 | -1 | 0 | 478 | D | |||||||||||||||
12/23/20 21:12 | 12/21/20 | OCX | Health | Diagn | In Vitro & In Vivo Diagnostic | Kingsley Alfred D | NY | D | S.dm | -13 | 0.3055 | 0 | -43 | -9 | 413 | D | |||||||||||||||
1/6/20 17:00 | 1/2/20 | OCX | Health | BioPrd | Biological Products, (No Diag | Lineage Cell Therapeutics, Inc. | CA | H | Previous | S | -5,138 | 2.16 | 0 | -2,383 | -28 | 6,041 | D | ||||||||||||||
9/13/19 17:20 | 9/11/19 | OCX | Health | BioPrd | Biological Products, (No Diag | Lineage Cell Therapeutics, Inc. | CA | T | S | -6,640 | 1.66 | 0 | -4,000 | -32 | 8,424 | D | |||||||||||||||
7/5/19 16:32 | 7/5/19 | OCX | Health | BioPrd | Biological Products, (No Diag | Biotime Inc | CA | T | S | -4,500 | 2.00 | 0 | -2,250 | -15 | 12,424 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |